TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Drugs for Oncology Market Research Report 2024(Status and Outlook)

Global Drugs for Oncology Market Research Report 2024(Status and Outlook)

  • Category:Life Sciences
  • Published on : 13 September 2024
  • Pages :
  • Formats:
  • Report Code:SMR-8004292

Report Overview
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
This report provides a deep insight into the global Drugs for Oncology market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Drugs for Oncology Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Drugs for Oncology market in any manner.
Global Drugs for Oncology Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences

Market Segmentation (by Type)
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others

Market Segmentation (by Application)
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Others

Geographic Segmentation
? North America (USA, Canada, Mexico)
? Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
? Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
? South America (Brazil, Argentina, Columbia, Rest of South America)
? The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:
? Industry drivers, restraints, and opportunities covered in the study
? Neutral perspective on the market performance
? Recent industry trends and developments
? Competitive landscape & strategies of key players
? Potential & niche segments and regions exhibiting promising growth covered
? Historical, current, and projected market size, in terms of value
? In-depth analysis of the Drugs for Oncology Market
? Overview of the regional outlook of the Drugs for Oncology Market:

Key Reasons to Buy this Report:
? Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
? This enables you to anticipate market changes to remain ahead of your competitors
? You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
? The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
? Provision of market value (USD Billion) data for each segment and sub-segment
? Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
? Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
? Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
? Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
? The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
? Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
? Provides insight into the market through Value Chain
? Market dynamics scenario, along with growth opportunities of the market in the years to come
? 6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Oncology Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

TABLE OF CONTENTS

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Drugs for Oncology
1.2 Key Market Segments
1.2.1 Drugs for Oncology Segment by Type
1.2.2 Drugs for Oncology Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Drugs for Oncology Market Overview
2.1 Global Market Overview
2.1.1 Global Drugs for Oncology Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Drugs for Oncology Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Drugs for Oncology Market Competitive Landscape
3.1 Global Drugs for Oncology Sales by Manufacturers (2019-2024)
3.2 Global Drugs for Oncology Revenue Market Share by Manufacturers (2019-2024)
3.3 Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Drugs for Oncology Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Drugs for Oncology Sales Sites, Area Served, Product Type
3.6 Drugs for Oncology Market Competitive Situation and Trends
3.6.1 Drugs for Oncology Market Concentration Rate
3.6.2 Global 5 and 10 Largest Drugs for Oncology Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Drugs for Oncology Industry Chain Analysis
4.1 Drugs for Oncology Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Drugs for Oncology Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Drugs for Oncology Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Drugs for Oncology Sales Market Share by Type (2019-2024)
6.3 Global Drugs for Oncology Market Size Market Share by Type (2019-2024)
6.4 Global Drugs for Oncology Price by Type (2019-2024)
7 Drugs for Oncology Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Drugs for Oncology Market Sales by Application (2019-2024)
7.3 Global Drugs for Oncology Market Size (M USD) by Application (2019-2024)
7.4 Global Drugs for Oncology Sales Growth Rate by Application (2019-2024)
8 Drugs for Oncology Market Segmentation by Region
8.1 Global Drugs for Oncology Sales by Region
8.1.1 Global Drugs for Oncology Sales by Region
8.1.2 Global Drugs for Oncology Sales Market Share by Region
8.2 North America
8.2.1 North America Drugs for Oncology Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Drugs for Oncology Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Drugs for Oncology Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Drugs for Oncology Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Drugs for Oncology Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Roche
9.1.1 Roche Drugs for Oncology Basic Information
9.1.2 Roche Drugs for Oncology Product Overview
9.1.3 Roche Drugs for Oncology Product Market Performance
9.1.4 Roche Business Overview
9.1.5 Roche Drugs for Oncology SWOT Analysis
9.1.6 Roche Recent Developments
9.2 Celgene
9.2.1 Celgene Drugs for Oncology Basic Information
9.2.2 Celgene Drugs for Oncology Product Overview
9.2.3 Celgene Drugs for Oncology Product Market Performance
9.2.4 Celgene Business Overview
9.2.5 Celgene Drugs for Oncology SWOT Analysis
9.2.6 Celgene Recent Developments
9.3 Novartis
9.3.1 Novartis Drugs for Oncology Basic Information
9.3.2 Novartis Drugs for Oncology Product Overview
9.3.3 Novartis Drugs for Oncology Product Market Performance
9.3.4 Novartis Drugs for Oncology SWOT Analysis
9.3.5 Novartis Business Overview
9.3.6 Novartis Recent Developments
9.4 Bristol-Myers Squibb
9.4.1 Bristol-Myers Squibb Drugs for Oncology Basic Information
9.4.2 Bristol-Myers Squibb Drugs for Oncology Product Overview
9.4.3 Bristol-Myers Squibb Drugs for Oncology Product Market Performance
9.4.4 Bristol-Myers Squibb Business Overview
9.4.5 Bristol-Myers Squibb Recent Developments
9.5 Johnson and Johnson
9.5.1 Johnson and Johnson Drugs for Oncology Basic Information
9.5.2 Johnson and Johnson Drugs for Oncology Product Overview
9.5.3 Johnson and Johnson Drugs for Oncology Product Market Performance
9.5.4 Johnson and Johnson Business Overview
9.5.5 Johnson and Johnson Recent Developments
9.6 Merck and Co.
9.6.1 Merck and Co. Drugs for Oncology Basic Information
9.6.2 Merck and Co. Drugs for Oncology Product Overview
9.6.3 Merck and Co. Drugs for Oncology Product Market Performance
9.6.4 Merck and Co. Business Overview
9.6.5 Merck and Co. Recent Developments
9.7 AstraZeneca
9.7.1 AstraZeneca Drugs for Oncology Basic Information
9.7.2 AstraZeneca Drugs for Oncology Product Overview
9.7.3 AstraZeneca Drugs for Oncology Product Market Performance
9.7.4 AstraZeneca Business Overview
9.7.5 AstraZeneca Recent Developments
9.8 Pfizer
9.8.1 Pfizer Drugs for Oncology Basic Information
9.8.2 Pfizer Drugs for Oncology Product Overview
9.8.3 Pfizer Drugs for Oncology Product Market Performance
9.8.4 Pfizer Business Overview
9.8.5 Pfizer Recent Developments
9.9 Amgen
9.9.1 Amgen Drugs for Oncology Basic Information
9.9.2 Amgen Drugs for Oncology Product Overview
9.9.3 Amgen Drugs for Oncology Product Market Performance
9.9.4 Amgen Business Overview
9.9.5 Amgen Recent Developments
9.10 Eli Lilly
9.10.1 Eli Lilly Drugs for Oncology Basic Information
9.10.2 Eli Lilly Drugs for Oncology Product Overview
9.10.3 Eli Lilly Drugs for Oncology Product Market Performance
9.10.4 Eli Lilly Business Overview
9.10.5 Eli Lilly Recent Developments
9.11 AbbVie
9.11.1 AbbVie Drugs for Oncology Basic Information
9.11.2 AbbVie Drugs for Oncology Product Overview
9.11.3 AbbVie Drugs for Oncology Product Market Performance
9.11.4 AbbVie Business Overview
9.11.5 AbbVie Recent Developments
9.12 Takeda
9.12.1 Takeda Drugs for Oncology Basic Information
9.12.2 Takeda Drugs for Oncology Product Overview
9.12.3 Takeda Drugs for Oncology Product Market Performance
9.12.4 Takeda Business Overview
9.12.5 Takeda Recent Developments
9.13 Astellas
9.13.1 Astellas Drugs for Oncology Basic Information
9.13.2 Astellas Drugs for Oncology Product Overview
9.13.3 Astellas Drugs for Oncology Product Market Performance
9.13.4 Astellas Business Overview
9.13.5 Astellas Recent Developments
9.14 Ipsen
9.14.1 Ipsen Drugs for Oncology Basic Information
9.14.2 Ipsen Drugs for Oncology Product Overview
9.14.3 Ipsen Drugs for Oncology Product Market Performance
9.14.4 Ipsen Business Overview
9.14.5 Ipsen Recent Developments
9.15 Sanofi
9.15.1 Sanofi Drugs for Oncology Basic Information
9.15.2 Sanofi Drugs for Oncology Product Overview
9.15.3 Sanofi Drugs for Oncology Product Market Performance
9.15.4 Sanofi Business Overview
9.15.5 Sanofi Recent Developments
9.16 Bayer
9.16.1 Bayer Drugs for Oncology Basic Information
9.16.2 Bayer Drugs for Oncology Product Overview
9.16.3 Bayer Drugs for Oncology Product Market Performance
9.16.4 Bayer Business Overview
9.16.5 Bayer Recent Developments
9.17 Biogen Idec
9.17.1 Biogen Idec Drugs for Oncology Basic Information
9.17.2 Biogen Idec Drugs for Oncology Product Overview
9.17.3 Biogen Idec Drugs for Oncology Product Market Performance
9.17.4 Biogen Idec Business Overview
9.17.5 Biogen Idec Recent Developments
9.18 Teva
9.18.1 Teva Drugs for Oncology Basic Information
9.18.2 Teva Drugs for Oncology Product Overview
9.18.3 Teva Drugs for Oncology Product Market Performance
9.18.4 Teva Business Overview
9.18.5 Teva Recent Developments
9.19 Otsuka
9.19.1 Otsuka Drugs for Oncology Basic Information
9.19.2 Otsuka Drugs for Oncology Product Overview
9.19.3 Otsuka Drugs for Oncology Product Market Performance
9.19.4 Otsuka Business Overview
9.19.5 Otsuka Recent Developments
9.20 Eisai
9.20.1 Eisai Drugs for Oncology Basic Information
9.20.2 Eisai Drugs for Oncology Product Overview
9.20.3 Eisai Drugs for Oncology Product Market Performance
9.20.4 Eisai Business Overview
9.20.5 Eisai Recent Developments
9.21 Merck KGaA
9.21.1 Merck KGaA Drugs for Oncology Basic Information
9.21.2 Merck KGaA Drugs for Oncology Product Overview
9.21.3 Merck KGaA Drugs for Oncology Product Market Performance
9.21.4 Merck KGaA Business Overview
9.21.5 Merck KGaA Recent Developments
9.22 Gilead Sciences
9.22.1 Gilead Sciences Drugs for Oncology Basic Information
9.22.2 Gilead Sciences Drugs for Oncology Product Overview
9.22.3 Gilead Sciences Drugs for Oncology Product Market Performance
9.22.4 Gilead Sciences Business Overview
9.22.5 Gilead Sciences Recent Developments
10 Drugs for Oncology Market Forecast by Region
10.1 Global Drugs for Oncology Market Size Forecast
10.2 Global Drugs for Oncology Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Drugs for Oncology Market Size Forecast by Country
10.2.3 Asia Pacific Drugs for Oncology Market Size Forecast by Region
10.2.4 South America Drugs for Oncology Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Drugs for Oncology by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Drugs for Oncology Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Drugs for Oncology by Type (2025-2030)
11.1.2 Global Drugs for Oncology Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Drugs for Oncology by Type (2025-2030)
11.2 Global Drugs for Oncology Market Forecast by Application (2025-2030)
11.2.1 Global Drugs for Oncology Sales (Kilotons) Forecast by Application
11.2.2 Global Drugs for Oncology Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings

LIST OF TABLES & FIGURES

List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Drugs for Oncology Market Size Comparison by Region (M USD)
Table 5. Global Drugs for Oncology Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Drugs for Oncology Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Drugs for Oncology Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Drugs for Oncology Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Oncology as of 2022)
Table 10. Global Market Drugs for Oncology Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Drugs for Oncology Sales Sites and Area Served
Table 12. Manufacturers Drugs for Oncology Product Type
Table 13. Global Drugs for Oncology Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Drugs for Oncology
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Drugs for Oncology Market Challenges
Table 22. Global Drugs for Oncology Sales by Type (Kilotons)
Table 23. Global Drugs for Oncology Market Size by Type (M USD)
Table 24. Global Drugs for Oncology Sales (Kilotons) by Type (2019-2024)
Table 25. Global Drugs for Oncology Sales Market Share by Type (2019-2024)
Table 26. Global Drugs for Oncology Market Size (M USD) by Type (2019-2024)
Table 27. Global Drugs for Oncology Market Size Share by Type (2019-2024)
Table 28. Global Drugs for Oncology Price (USD/Ton) by Type (2019-2024)
Table 29. Global Drugs for Oncology Sales (Kilotons) by Application
Table 30. Global Drugs for Oncology Market Size by Application
Table 31. Global Drugs for Oncology Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Drugs for Oncology Sales Market Share by Application (2019-2024)
Table 33. Global Drugs for Oncology Sales by Application (2019-2024) & (M USD)
Table 34. Global Drugs for Oncology Market Share by Application (2019-2024)
Table 35. Global Drugs for Oncology Sales Growth Rate by Application (2019-2024)
Table 36. Global Drugs for Oncology Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Drugs for Oncology Sales Market Share by Region (2019-2024)
Table 38. North America Drugs for Oncology Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Drugs for Oncology Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Drugs for Oncology Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Drugs for Oncology Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Drugs for Oncology Sales by Region (2019-2024) & (Kilotons)
Table 43. Roche Drugs for Oncology Basic Information
Table 44. Roche Drugs for Oncology Product Overview
Table 45. Roche Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Roche Business Overview
Table 47. Roche Drugs for Oncology SWOT Analysis
Table 48. Roche Recent Developments
Table 49. Celgene Drugs for Oncology Basic Information
Table 50. Celgene Drugs for Oncology Product Overview
Table 51. Celgene Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Celgene Business Overview
Table 53. Celgene Drugs for Oncology SWOT Analysis
Table 54. Celgene Recent Developments
Table 55. Novartis Drugs for Oncology Basic Information
Table 56. Novartis Drugs for Oncology Product Overview
Table 57. Novartis Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Novartis Drugs for Oncology SWOT Analysis
Table 59. Novartis Business Overview
Table 60. Novartis Recent Developments
Table 61. Bristol-Myers Squibb Drugs for Oncology Basic Information
Table 62. Bristol-Myers Squibb Drugs for Oncology Product Overview
Table 63. Bristol-Myers Squibb Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Bristol-Myers Squibb Business Overview
Table 65. Bristol-Myers Squibb Recent Developments
Table 66. Johnson and Johnson Drugs for Oncology Basic Information
Table 67. Johnson and Johnson Drugs for Oncology Product Overview
Table 68. Johnson and Johnson Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Johnson and Johnson Business Overview
Table 70. Johnson and Johnson Recent Developments
Table 71. Merck and Co. Drugs for Oncology Basic Information
Table 72. Merck and Co. Drugs for Oncology Product Overview
Table 73. Merck and Co. Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Merck and Co. Business Overview
Table 75. Merck and Co. Recent Developments
Table 76. AstraZeneca Drugs for Oncology Basic Information
Table 77. AstraZeneca Drugs for Oncology Product Overview
Table 78. AstraZeneca Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. AstraZeneca Business Overview
Table 80. AstraZeneca Recent Developments
Table 81. Pfizer Drugs for Oncology Basic Information
Table 82. Pfizer Drugs for Oncology Product Overview
Table 83. Pfizer Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Pfizer Business Overview
Table 85. Pfizer Recent Developments
Table 86. Amgen Drugs for Oncology Basic Information
Table 87. Amgen Drugs for Oncology Product Overview
Table 88. Amgen Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Amgen Business Overview
Table 90. Amgen Recent Developments
Table 91. Eli Lilly Drugs for Oncology Basic Information
Table 92. Eli Lilly Drugs for Oncology Product Overview
Table 93. Eli Lilly Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Eli Lilly Business Overview
Table 95. Eli Lilly Recent Developments
Table 96. AbbVie Drugs for Oncology Basic Information
Table 97. AbbVie Drugs for Oncology Product Overview
Table 98. AbbVie Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. AbbVie Business Overview
Table 100. AbbVie Recent Developments
Table 101. Takeda Drugs for Oncology Basic Information
Table 102. Takeda Drugs for Oncology Product Overview
Table 103. Takeda Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Takeda Business Overview
Table 105. Takeda Recent Developments
Table 106. Astellas Drugs for Oncology Basic Information
Table 107. Astellas Drugs for Oncology Product Overview
Table 108. Astellas Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Astellas Business Overview
Table 110. Astellas Recent Developments
Table 111. Ipsen Drugs for Oncology Basic Information
Table 112. Ipsen Drugs for Oncology Product Overview
Table 113. Ipsen Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Ipsen Business Overview
Table 115. Ipsen Recent Developments
Table 116. Sanofi Drugs for Oncology Basic Information
Table 117. Sanofi Drugs for Oncology Product Overview
Table 118. Sanofi Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 119. Sanofi Business Overview
Table 120. Sanofi Recent Developments
Table 121. Bayer Drugs for Oncology Basic Information
Table 122. Bayer Drugs for Oncology Product Overview
Table 123. Bayer Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 124. Bayer Business Overview
Table 125. Bayer Recent Developments
Table 126. Biogen Idec Drugs for Oncology Basic Information
Table 127. Biogen Idec Drugs for Oncology Product Overview
Table 128. Biogen Idec Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 129. Biogen Idec Business Overview
Table 130. Biogen Idec Recent Developments
Table 131. Teva Drugs for Oncology Basic Information
Table 132. Teva Drugs for Oncology Product Overview
Table 133. Teva Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 134. Teva Business Overview
Table 135. Teva Recent Developments
Table 136. Otsuka Drugs for Oncology Basic Information
Table 137. Otsuka Drugs for Oncology Product Overview
Table 138. Otsuka Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 139. Otsuka Business Overview
Table 140. Otsuka Recent Developments
Table 141. Eisai Drugs for Oncology Basic Information
Table 142. Eisai Drugs for Oncology Product Overview
Table 143. Eisai Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 144. Eisai Business Overview
Table 145. Eisai Recent Developments
Table 146. Merck KGaA Drugs for Oncology Basic Information
Table 147. Merck KGaA Drugs for Oncology Product Overview
Table 148. Merck KGaA Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 149. Merck KGaA Business Overview
Table 150. Merck KGaA Recent Developments
Table 151. Gilead Sciences Drugs for Oncology Basic Information
Table 152. Gilead Sciences Drugs for Oncology Product Overview
Table 153. Gilead Sciences Drugs for Oncology Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 154. Gilead Sciences Business Overview
Table 155. Gilead Sciences Recent Developments
Table 156. Global Drugs for Oncology Sales Forecast by Region (2025-2030) & (Kilotons)
Table 157. Global Drugs for Oncology Market Size Forecast by Region (2025-2030) & (M USD)
Table 158. North America Drugs for Oncology Sales Forecast by Country (2025-2030) & (Kilotons)
Table 159. North America Drugs for Oncology Market Size Forecast by Country (2025-2030) & (M USD)
Table 160. Europe Drugs for Oncology Sales Forecast by Country (2025-2030) & (Kilotons)
Table 161. Europe Drugs for Oncology Market Size Forecast by Country (2025-2030) & (M USD)
Table 162. Asia Pacific Drugs for Oncology Sales Forecast by Region (2025-2030) & (Kilotons)
Table 163. Asia Pacific Drugs for Oncology Market Size Forecast by Region (2025-2030) & (M USD)
Table 164. South America Drugs for Oncology Sales Forecast by Country (2025-2030) & (Kilotons)
Table 165. South America Drugs for Oncology Market Size Forecast by Country (2025-2030) & (M USD)
Table 166. Middle East and Africa Drugs for Oncology Consumption Forecast by Country (2025-2030) & (Units)
Table 167. Middle East and Africa Drugs for Oncology Market Size Forecast by Country (2025-2030) & (M USD)
Table 168. Global Drugs for Oncology Sales Forecast by Type (2025-2030) & (Kilotons)
Table 169. Global Drugs for Oncology Market Size Forecast by Type (2025-2030) & (M USD)
Table 170. Global Drugs for Oncology Price Forecast by Type (2025-2030) & (USD/Ton)
Table 171. Global Drugs for Oncology Sales (Kilotons) Forecast by Application (2025-2030)
Table 172. Global Drugs for Oncology Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Drugs for Oncology
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Drugs for Oncology Market Size (M USD), 2019-2030
Figure 5. Global Drugs for Oncology Market Size (M USD) (2019-2030)
Figure 6. Global Drugs for Oncology Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Drugs for Oncology Market Size by Country (M USD)
Figure 11. Drugs for Oncology Sales Share by Manufacturers in 2023
Figure 12. Global Drugs for Oncology Revenue Share by Manufacturers in 2023
Figure 13. Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Drugs for Oncology Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Drugs for Oncology Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Drugs for Oncology Market Share by Type
Figure 18. Sales Market Share of Drugs for Oncology by Type (2019-2024)
Figure 19. Sales Market Share of Drugs for Oncology by Type in 2023
Figure 20. Market Size Share of Drugs for Oncology by Type (2019-2024)
Figure 21. Market Size Market Share of Drugs for Oncology by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Drugs for Oncology Market Share by Application
Figure 24. Global Drugs for Oncology Sales Market Share by Application (2019-2024)
Figure 25. Global Drugs for Oncology Sales Market Share by Application in 2023
Figure 26. Global Drugs for Oncology Market Share by Application (2019-2024)
Figure 27. Global Drugs for Oncology Market Share by Application in 2023
Figure 28. Global Drugs for Oncology Sales Growth Rate by Application (2019-2024)
Figure 29. Global Drugs for Oncology Sales Market Share by Region (2019-2024)
Figure 30. North America Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Drugs for Oncology Sales Market Share by Country in 2023
Figure 32. U.S. Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Drugs for Oncology Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Drugs for Oncology Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Drugs for Oncology Sales Market Share by Country in 2023
Figure 37. Germany Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Drugs for Oncology Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Drugs for Oncology Sales Market Share by Region in 2023
Figure 44. China Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Drugs for Oncology Sales and Growth Rate (Kilotons)
Figure 50. South America Drugs for Oncology Sales Market Share by Country in 2023
Figure 51. Brazil Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Drugs for Oncology Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Drugs for Oncology Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Drugs for Oncology Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Drugs for Oncology Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Drugs for Oncology Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Drugs for Oncology Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Drugs for Oncology Market Share Forecast by Type (2025-2030)
Figure 65. Global Drugs for Oncology Sales Forecast by Application (2025-2030)
Figure 66. Global Drugs for Oncology Market Share Forecast by Application (2025-2030)

Offer REPORT BUYING OPTIONS

USD GBP EURO YEN Single User Price
USD GBP EURO YEN Multi User Price
USD GBP EURO YEN Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount